BioCentury | May 6, 2020
Politics, Policy & Law

Bright shines harsh light on America’s COVID-19 preparedness, FDA’s independence

...discussions about BARDA contracting, including in 2017 when Bright declined to extend a contract to Aeolus Pharmaceuticals Inc....
...OTCQX:AOLS). “In attempting to justify the extension of this failed contract, Mr. Clerici emphasized that Aeolus’s...
...a friend of Jared Kushner, President Trump’s son-in-law and a Senior Advisor to the President.” Aeolus...
BioCentury | Nov 9, 2019
Company News

Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange

...NYSE:TFX). Cancer company Partner Therapeutics, Inc. hired John McManus as CBO. He was CEO of Aeolus Pharmaceuticals Inc....
BioCentury | Mar 2, 2018
Clinical News

Arca reports Phase IIb data for Gencaro in heart failure patients

...atrial flutter. Arca has rights to Gencaro from CPEC LLC, a company jointly owned by Aeolus Pharmaceuticals Inc....
...Fast Track designation in the U.S. to prevent AF/atrial flutter in patients with reduced LVEF. Aeolus Pharmaceuticals Inc....
...in the setting of AF or atrial flutter Status: Phase IIb data Milestone: NA Chris Lieu bucindolol hydrochloride Gencaro Aeolus Pharmaceuticals Inc. Arca...
BioCentury | Feb 24, 2017
Clinical News

AEOL 10150: Ph I started

...contract with HHS’s Biomedical Advanced Research and Development Authority (BARDA) worth up to $118.4 million. Aeolus...
...treat idiopathic pulmonary fibrosis (IPF) and for use with radiation therapy to treat solid tumors. Aeolus Pharmaceuticals Inc....
...acute radiation exposure Endpoint: Safety and pharmacokinetics Status: Phase I started Milestone: NA Julian Zhu AEOL 10150 manganese porphyrin Aeolus Pharmaceuticals Inc. BARDA...
BioCentury | Dec 21, 2015
Financial News

Aeolus completes private placement of convertible preferred stock and warrants

Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif. Business: Neurology, Pulmonary, Autoimmune Date completed: 2015-12-14 Type: Private placement of convertible preferred stock and warrants Raised: $4.5 million Shares outstanding prior: 135.9 million Placement agent: Laidlaw Investor:...
BioCentury | Dec 21, 2015
Financial News

Aeolus completes private placement of common stock and warrants

Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif. Business: Neurology, Pulmonary, Autoimmune Date completed: 2015-12-14 Type: Private placement of common stock and warrants Raised: $2.2 million Shares: 10.2 million Price: $0.22 Shares after offering: 146.1 million...
BioCentury | Oct 29, 2015
Emerging Company Profile

Rebuilding the barrier

...companies have disclosed programs targeting leukocyte-vascular interactions to treat epilepsy, but at least one - Aeolus Pharmaceuticals Inc....
...covering methods of targeting integrin α4 and SELP to treat epilepsy. Companies and Institutions Mentioned Aeolus Pharmaceuticals Inc....
BioCentury | Aug 24, 2015
Clinical News

Aeolus preclinical data

...respiration. Data were published in Neurobiology of Disease. AEOL 10150 is a catalytic manganoporphyrin antioxidant. Aeolus Pharmaceuticals Inc....
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: DNA-directed DNA polymerase γ (POLG)

...Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a scavengers of ROS and peroxynitrites, to treat Cockayne syndrome. Aeolus Pharmaceuticals Inc....
BioCentury | Apr 27, 2015
Clinical News

Gencaro bucindolol regulatory update

...company jointly owned by Aeolus and Endo. CPEC gained rights to Gencaro from Bristol-Myers Squibb. Aeolus...
Items per page:
1 - 10 of 170
BioCentury | May 6, 2020
Politics, Policy & Law

Bright shines harsh light on America’s COVID-19 preparedness, FDA’s independence

...discussions about BARDA contracting, including in 2017 when Bright declined to extend a contract to Aeolus Pharmaceuticals Inc....
...OTCQX:AOLS). “In attempting to justify the extension of this failed contract, Mr. Clerici emphasized that Aeolus’s...
...a friend of Jared Kushner, President Trump’s son-in-law and a Senior Advisor to the President.” Aeolus...
BioCentury | Nov 9, 2019
Company News

Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange

...NYSE:TFX). Cancer company Partner Therapeutics, Inc. hired John McManus as CBO. He was CEO of Aeolus Pharmaceuticals Inc....
BioCentury | Mar 2, 2018
Clinical News

Arca reports Phase IIb data for Gencaro in heart failure patients

...atrial flutter. Arca has rights to Gencaro from CPEC LLC, a company jointly owned by Aeolus Pharmaceuticals Inc....
...Fast Track designation in the U.S. to prevent AF/atrial flutter in patients with reduced LVEF. Aeolus Pharmaceuticals Inc....
...in the setting of AF or atrial flutter Status: Phase IIb data Milestone: NA Chris Lieu bucindolol hydrochloride Gencaro Aeolus Pharmaceuticals Inc. Arca...
BioCentury | Feb 24, 2017
Clinical News

AEOL 10150: Ph I started

...contract with HHS’s Biomedical Advanced Research and Development Authority (BARDA) worth up to $118.4 million. Aeolus...
...treat idiopathic pulmonary fibrosis (IPF) and for use with radiation therapy to treat solid tumors. Aeolus Pharmaceuticals Inc....
...acute radiation exposure Endpoint: Safety and pharmacokinetics Status: Phase I started Milestone: NA Julian Zhu AEOL 10150 manganese porphyrin Aeolus Pharmaceuticals Inc. BARDA...
BioCentury | Dec 21, 2015
Financial News

Aeolus completes private placement of convertible preferred stock and warrants

Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif. Business: Neurology, Pulmonary, Autoimmune Date completed: 2015-12-14 Type: Private placement of convertible preferred stock and warrants Raised: $4.5 million Shares outstanding prior: 135.9 million Placement agent: Laidlaw Investor:...
BioCentury | Dec 21, 2015
Financial News

Aeolus completes private placement of common stock and warrants

Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif. Business: Neurology, Pulmonary, Autoimmune Date completed: 2015-12-14 Type: Private placement of common stock and warrants Raised: $2.2 million Shares: 10.2 million Price: $0.22 Shares after offering: 146.1 million...
BioCentury | Oct 29, 2015
Emerging Company Profile

Rebuilding the barrier

...companies have disclosed programs targeting leukocyte-vascular interactions to treat epilepsy, but at least one - Aeolus Pharmaceuticals Inc....
...covering methods of targeting integrin α4 and SELP to treat epilepsy. Companies and Institutions Mentioned Aeolus Pharmaceuticals Inc....
BioCentury | Aug 24, 2015
Clinical News

Aeolus preclinical data

...respiration. Data were published in Neurobiology of Disease. AEOL 10150 is a catalytic manganoporphyrin antioxidant. Aeolus Pharmaceuticals Inc....
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: DNA-directed DNA polymerase γ (POLG)

...Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a scavengers of ROS and peroxynitrites, to treat Cockayne syndrome. Aeolus Pharmaceuticals Inc....
BioCentury | Apr 27, 2015
Clinical News

Gencaro bucindolol regulatory update

...company jointly owned by Aeolus and Endo. CPEC gained rights to Gencaro from Bristol-Myers Squibb. Aeolus...
Items per page:
1 - 10 of 170